A generic image of stock metrics
Markets

Bristol Myers Upgraded to “Buy” at Goldman Sachs (BMY)

Pharmaceuticals maker Bristol Myers Squibb Co. ( BMY ) on Thursday caught a big upgrade from analysts at Goldman Sachs.

The firm said it boosted its rating on BMY from "Neutral" to "Buy" with a $37 price target. That target suggests an expected 20% upside to the stock's Wednesday closing price of $30.95.

Goldman made the call amid a broad upgrade of the Largecap Pharma sector to "Attractive." The firm commented that "high margin contribution from new drugs (estimated 69% of sales by 2016) should more than offset nearterm margin erosion from upcoming patent expirations." It also sees good earnings visibility from BMY post 2013 and expects consensus earnings estimates for the company to be raised within the next year.

Bristol Myers shares fell 38 cents, or -1.2%, in premarket trading Thursday.

The Bottom Line

We have been recommending shares of Bristol Myers ( BMY ) since Aug.25, 2009, when the stock was trading at $22.58. The company has a 4.26% dividend yield, based on last night's closing stock price of $30.95.

Bristol Myers Squibb Co. ( BMY ) is a "Highly Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.8 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMY

Other Topics

Stocks

Latest Markets Videos